GSK and Partners Bavarian Nordic and J&J Ebola vaccine candidates both reach Phase II

17/07/2015 - 2 minutes

In outbreak situations such as the Ebola crisis, vaccines play an essential role that was largely needed during the 2014 health emergency, especially when the plague reached the First World. To ensure preparedness against Ebola, now and in the future, companies have been rushing to develop vaccines against this disease. GSK has come up with its own vaccine, and the collaboration between Bavarian Nordic and Johnson&Johnson has resulted with an alternative treatment. Today, both candidates are starting Phase II.

The ebola epidemic has been contained thanks of the efforts of the World Health Organization, local governments and other non-governmental organizations, such as Doctors Without Borders. However, “contained” doesn’t mean cured. Liberia, which was declared free of the disease, reported two new deaths caused by the virus and the fear of resurgence has been keeping people away from the volunteers’ recruiters.

Nevertheless, Bavarian Nordic and its partner Janssen, J&J’ subsidiary, finally enrolled enough volunteers and have launched the Phase II clinical trial in the UK and France.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!